Ceribell vs NeuroPace
CBLL and NPCE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CBLL and NPCE compare
Ceribell is the larger company, worth 2.5 times as much as NeuroPace ($1.1B against $430M).
Ceribell grew revenue faster over the last twelve months (31.7% versus 16.9% for NeuroPace).
NeuroPace keeps more of each dollar of sales as profit, with a net margin of −19.3% compared with −64.7% at Ceribell.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CBLL | NPCE |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $430M |
| Share price | $27.80 | $12.52 |
| Change, 1 year | 136% | −6.9% |
| Change, 5 years | – | 5.7% |
| Beta (5Y) | 0.84 | 1.07 |
| Employees | 327 | 209 |
| StockData Score | ||
| Total score | 6 | 6 |
| Valuation score | 0 | 0 |
| Growth score | 3 | 4 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.5× | 4.3× (better) |
| P/B | 8.3× (better) | 36.2× |
| FCF yield | −5.1% | −2.7% (better) |
| Fair value | $11.11 | $6.55 |
| Margin of safety | −150% | −91.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 31.7% (better) | 16.9% |
| Revenue growth, 5Y average | – | 19.4% |
| Profitability | ||
| Gross margin | 88.9% (better) | 79.6% |
| Operating margin | −68.6% | −15.3% (better) |
| Net margin | −64.7% | −19.3% (better) |
| FCF margin | −53.7% | −11.7% (better) |
| Return on equity | −43.9% (better) | −122% |
| Return on invested capital | −331% | −67.8% (better) |
| Financial health | ||
| Debt / equity | 0.16 (better) | 4.97 |
| Interest coverage | −38.6× | −2.4× (better) |
| Current ratio | 9.18 (better) | 4.94 |
| Altman Z-score | 14.89 (better) | −3.77 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 79.5% | 77.4% |
| Held by insiders | 26.7% | 16.6% |
| Insider net buying, 12 months | −$22.4M | −$399K (better) |
| Short interest, % of float | 7.0% | 3.0% |
Go deeper
- CBLL stock overview
- CBLL income statement
- CBLL valuation and score
- NPCE stock overview
- NPCE income statement
- NPCE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.